SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants

Mar 6, 2018

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Mar 5, 2018

SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018

Feb 1, 2018

SCYNEXIS Provides Corporate and SCY-078 Pipeline Update

Jan 4, 2018

SCYNEXIS to Participate in Upcoming Investor Conferences

Nov 28, 2017

SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference

Nov 22, 2017

SCYNEXIS Appoints Scott Sukenick as General Counsel

Nov 16, 2017

SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update

Nov 7, 2017

SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017

Oct 5, 2017

SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017

Sep 27, 2017